JAKARTA – PT Prodia Widyahusada Tbk (PRDA), the company that oversees the Prodia laboratory network, is still experiencing a downward trend in net profit until September 2024. In the first nine months of this year, the company's net profit was seen weakening by 17.5% year-on-year ( yo).

This decrease in profit is the impact of a slight correction in revenue of 0.9% yoy at the end of September 2024, from IDR 1.61 trillion to IDR 1.60 trillion. "However, this gain shows a positive improvement of 3.8% from the revenue performance in the second quarter of 2024," said management optimistically.

Apart from that, several of Prodia's expense items appear to have swelled, especially operational expenses which rose 5.35% yoy and other expenses which increased more than 3 times.

In the end, PRDA recorded a net profit of IDR 194.17 billion as of September 2024, slipping far from IDR 235.5 billion recorded in the same period last year.

Responding to this, Dewi Muliaty, President Director of Prodia, still admitted that she was optimistic about being able to record a positive trend until the end of 2024. "This optimism is also driven by the increasing demand for health checks from corporate clients," she said in an official broadcast quoted today (1/11) .

Even though the corporate client segment is currently facing tight competition, Muliaty admitted that he still hopes for positive results at the end of the fourth quarter.

"Apart from that, the Company is also in the process of preparing a business model that will be implemented in 89 clinic branches out of the 152 available Prodia branches. "Through this clinic, we will segment and categorize the market based on the characteristics of each region," said Muliaty further regarding the growth strategy. (ZH/LM)